VOR (Vor Biopharma) Float Percentage Of Total Shares Outstanding : 75.07% (As of May. 03, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vor Biopharma's float shares is 93.73 Mil. Vor Biopharma's total shares outstanding is 124.85 Mil. Vor Biopharma's float percentage of total shares outstanding is 75.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vor Biopharma's Insider Ownership is 1.30%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vor Biopharma's Institutional Ownership is 48.81%.

Vor Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Vor Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	93.73	/	124.85
	=	75.07%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vor Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140

Website

https://www.vorbio.com

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Executives

Eyal C. Attar	officer: Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen	officer: Chief Financial Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak	officer: Chief Medical Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim	officer: Chief Technology Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty	officer: Chief Scientific Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang	director, officer: President and CEO	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107